Skip to main content
. Author manuscript; available in PMC: 2026 Aug 19.
Published in final edited form as: Ann Oncol. 2025 Dec 12;37(4):532–543. doi: 10.1016/j.annonc.2025.11.018

Figure 3. Efficacy for imlunestrant—abemaciclib versus imlunestrant alone in all patients.

Figure 3.

(A) Investigator-assessed progression-free survival, (B) investigator-assessed progression-free survival in patients previously treated with a CDK4/6i, and (C) overall survival.

CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; CI, confidence interval; NR, not reached.